Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067933 | 0.80 | CD4 (0.52) | ALDH1A1POLBKMT2AGAAPKM | |
| SCHEMBL5070054 | 0.79 | AKR1C3 (0.50) | POLBKMT2ASMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL5069414 | 0.79 | KMT2A (0.45) | KMT2ASMN1; SMN2CYP3A4CYP2C19NPSR1 | |
| SCHEMBL2805945 | 0.74 | MCOLN3 (0.48) | MCOLN3ALDH1A1POLBKMT2AUSP2 | |
| SCHEMBL3463347 | 0.72 | MCOLN3 (0.44) | MCOLN3ALDH1A1POLBKMT2AUSP2 | |
| SCHEMBL5072632 | 0.71 | MAPT (0.43) | ALDH1A1POLBKMT2ATSHRCYP3A4 | |
| SCHEMBL12719725 | 0.70 | MCOLN3 (0.54) | MCOLN3ALDH1A1POLBKMT2AUSP2 | |
| Hydrochloric Acid SCHEMBL1625417 | 0.69 | MCOLN3 (0.53) | MCOLN3ALDH1A1POLBKMT2AUSP2 | |
| SCHEMBL4182166 | 0.68 | MCOLN3 (0.69) | MCOLN3ALDH1A1POLBKMT2AUSP2 | |
| SCHEMBL6405875 | 0.67 | MCOLN3 (0.54) | MCOLN3ALDH1A1POLBKMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435820-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7109340-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2006-09-19 | — | — | US | disclosed |
| US-20060199837-A1 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE | AVENTIS PHARMA S.A. (FR) | 2006-09-07 | — | — | US | disclosed |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199837-A1 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE | BRD4, TP53, HCCS | MCOLN3 4554/4885ALDH1A1 1455/4885POLB 2932/4885 |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | BRD4, TP53, HCCS | MCOLN3 4530/4885ALDH1A1 1672/4885POLB 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.